VacZine Analytics  
MarketVIEW: MMR, MMRV and varicella vaccines

Published: Oct 2014

Measles, mumps and rubella can cause severe morbidity or even death in young children in underdeveloped countries. Because combination MMR vaccines (licensed since 1971) have led to a >99% reduction in these diseases in the US the WHO seeks to control these diseases globally. Example programs are the Measles & Rubella Initiative which has reduced global measles deaths from ~562,000 in 2000 to 122,000 in 2012 (mostly children <5yrs). The WHO recommends that two doses of measles vaccine are included in national immunization programmes (NIPs), one dose of rubella vaccine with varying policies/roll out on triple combination vaccines. For varicella, another important childhood disease a limited number of countries have added varicella vaccines to NIPs sometimes through MMRV.

This MarketVIEW is a comprehensive commercial opportunity assessment detailing the potential market for MMR, MMRV and varicella vaccines (doses 000s, $ 000s) to 2030 across Western markets, LATAM and key ROW markets. The forecast takes into account the introduction of new national immunization programs (NIPs) for varicella, launch of new products e.g. GSK's Priorix (US) and provides revenues per major competitor. Country specific dynamics with detailed vaccine coverage assumptions, doses variance are included along with description of future developments in GAVI/ROW countries.

THIS PRODUCT IS A SUMMARY PRESENTATION + 1 MODELS

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV058 Click here>>
Choose option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2014 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains